ADReCS

Pharmaceutical Information

Drug Name	Azathioprine
Drug ID	BADD_D00195
Description	Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic index.[A189678,A189687,A189690] Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of renal transplant rejection.[L11214] Azathiprine was granted FDA approval on 20 March 1968.[L11214]
Indications and Usage	Azathioprine is indicated to treat rheumatoid arthritis and prevent renal transplant rejection.[L11214]
Marketing Status	approved
ATC Code	L04AX01
DrugBank ID	DB00993
KEGG ID	D00238
MeSH ID	D001379
PubChem ID	2265
TTD Drug ID	D07QCE
NDC Product Code	62991-2189; 65649-231; 67877-492; 68084-229; 68382-120; 51407-182; 68382-118; 72789-129; 46014-1110; 70771-1141; 60219-1076; 60219-2036; 60219-2037; 68382-003; 48954-909; 51927-0071; 68682-241; 70518-3544; 70771-1140; 51927-2258; 54766-590; 65841-602; 12780-0300; 38779-0312; 66122-0009; 42291-063; 68462-502; 71610-124; 42291-071; 68682-231; 70771-1139; 15308-0732; 49452-0783; 67877-493; 51552-0779; 65649-241; 67877-494; 67877-495; 68382-119; 42973-143
UNII	MRK240IY2L
Synonyms	Azathioprine \| Azothioprine \| Imurel \| Imuran \| Immuran \| Azathioprine Sodium \| Sodium, Azathioprine \| Azathioprine Sodium Salt \| Azathioprine Sulfate

Chemical Information

Molecular Formula	C9H7N7O2S
CAS Registry Number	446-86-6
SMILES	CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-]
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Abdominal lymphadenopathy	07.11.01.018; 01.09.01.020	0.000627%		Not Available
Large intestinal stenosis	07.13.03.004	0.005546%
Anorectal swelling	07.03.03.008	0.000313%		Not Available
Phospholipidosis	14.08.04.025	0.000783%		Not Available
Infantile haemangioma	24.03.06.009; 16.02.01.007	0.000313%		Not Available
Gastrointestinal wall thickening	07.01.06.032	0.001097%		Not Available
Kidney congestion	20.02.03.015; 02.05.04.017	0.000470%		Not Available
Vein rupture	24.03.02.032; 12.01.11.011	-	-	Not Available
Non-cirrhotic portal hypertension	24.08.06.003; 09.01.06.019	0.002663%		Not Available
Acute erythroid leukaemia	16.01.05.006; 01.10.05.006	0.000313%		Not Available
Anal stenosis	07.13.05.004	-	-
Bell's palsy	17.04.03.011	-	-	Not Available
Blood loss anaemia	24.07.01.088; 01.03.02.018	0.000313%		Not Available
Choroid melanoma	16.34.04.001; 06.12.04.001	0.000313%		Not Available
Discharge	08.01.03.086	-	-	Not Available
Drug effect less than expected	08.06.01.036	-	-	Not Available
Eosinophilic granulomatosis with polyangiitis	22.01.01.025; 10.02.02.031; 01.02.04.022; 24.12.04.010	0.000313%		Not Available
Epstein Barr virus positive mucocutaneous ulcer	07.05.06.010; 01.13.02.006; 23.07.03.024; 16.21.02.006; 11.05.10.009	0.000627%		Not Available
Fear of injection	19.06.03.016	0.000846%		Not Available
Follicular lymphoma	01.15.08.002; 16.28.08.002	-	-	Not Available
Gait inability	08.01.02.011; 17.02.05.069	0.000940%		Not Available
Gastrointestinal lymphoma	01.17.01.006; 16.35.01.006; 07.21.04.014	0.001253%		Not Available
Gastrointestinal scarring	07.13.01.015	0.000470%		Not Available
Granulomatous lymphadenitis	11.07.01.022; 01.09.01.031	0.000470%		Not Available
Haemophagocytic lymphohistiocytosis	16.32.03.038; 10.02.01.077; 01.05.01.026	0.007519%		Not Available
Illness	08.01.03.091	-	-	Not Available
Immunoglobulin G4 related disease	15.06.01.020; 10.04.04.028	0.000313%		Not Available
Intestinal mucosal hypertrophy	07.11.01.040	0.000627%		Not Available
Intra-abdominal fluid collection	21.07.04.014; 07.07.01.014	0.000313%		Not Available
Loss of therapeutic response	08.06.01.041	-	-	Not Available

The 24th Page First Pre 24 25 Next Last Total 25 Pages